Literature DB >> 11920311

Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa.

Karl Albert Brokstad1, Jens-Christian Eriksson, Rebecca Jane Cox, Turid Tynning, Jan Olofsson, Roland Jonsson, Ake Davidsson.   

Abstract

The immune response in the nasal mucosa to influenza vaccination in 23 patients scheduled for tonsillectomy was studied. A statistically significant increase in influenza virus-specific serum and oral fluid antibodies was observed 7 days after vaccination. The numbers of influenza virus-specific antibody-secreting cells (ASCs) in peripheral blood also increased significantly 1 week after vaccination. The numbers of ASCs in tonsils and nasal mucosa were compared with data from a recent study of nonvaccinated volunteers. The numbers of influenza virus-specific ASCs in tonsils were significantly higher in the vaccinated group, but, surprisingly, there was no significant difference between the groups in the numbers of ASCs in nasal mucosa. This suggests that the influenza virus-specific antibodies detected in oral fluid are not produced locally in the nasal mucosa and may originate from a systemic source, indicating that the vaccination may favor a systemic immune response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920311     DOI: 10.1086/339710

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

Review 1.  Mucosal immunization in perspective.

Authors:  Markus A Rose
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 2.  Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly.

Authors:  Monique P Curran; Isabel Leroux-Roels
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

3.  Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines.

Authors:  Sanae Sasaki; Maria C Jaimes; Tyson H Holmes; Cornelia L Dekker; Kutubuddin Mahmood; George W Kemble; Ann M Arvin; Harry B Greenberg
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

4.  Ginsan enhances humoral antibody response to orally delivered antigen.

Authors:  Hee Sam Na; You Jin Lim; Yeon-Sook Yun; Mi Na Kweon; Hyun-Chul Lee
Journal:  Immune Netw       Date:  2010-02-28       Impact factor: 6.303

5.  Rapid cloning of high-affinity human monoclonal antibodies against influenza virus.

Authors:  Jens Wrammert; Kenneth Smith; Joe Miller; William A Langley; Kenneth Kokko; Christian Larsen; Nai-Ying Zheng; Israel Mays; Lori Garman; Christina Helms; Judith James; Gillian M Air; J Donald Capra; Rafi Ahmed; Patrick C Wilson
Journal:  Nature       Date:  2008-04-30       Impact factor: 49.962

6.  Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel® sponges.

Authors:  Katherine H Parker; Troy J Kemp; Yuanji Pan; Zhen Yang; Anna R Giuliano; Ligia A Pinto
Journal:  Vaccine       Date:  2018-04-06       Impact factor: 3.641

7.  B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination.

Authors:  Mark Y Sangster; Jane Baer; Felix W Santiago; Theresa Fitzgerald; Natalia A Ilyushina; Aarthi Sundararajan; Alicia D Henn; Florian Krammer; Hongmei Yang; Catherine J Luke; Martin S Zand; Peter F Wright; John J Treanor; David J Topham; Kanta Subbarao
Journal:  Clin Vaccine Immunol       Date:  2013-04-10

Review 8.  The human side of influenza.

Authors:  Christine M Oshansky; Paul G Thomas
Journal:  J Leukoc Biol       Date:  2012-02-23       Impact factor: 4.962

Review 9.  Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients.

Authors:  Arnt-Ove Hovden; Rebecca Jane Cox; Lars Reinhardt Haaheim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

10.  Invaplex functions as an intranasal adjuvant for subunit and DNA vaccines co-delivered in the nasal cavity of nonhuman primates.

Authors:  Jeremy V Camp; Robert L Wilson; Morgan Singletary; James L Blanchard; Anna Aldovini; Robert W Kaminski; Edwin V Oaks; Pamela A Kozlowski
Journal:  Vaccine X       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.